Medical Marijuana Sciences' Scientific Advisory Board Chairman Dr. Mark L. Rabe Presents to Pain Medicine and Other Physician...
April 25 2014 - 9:00AM
Medical Marijuana Sciences, Inc. (MMS), a subsidiary of Nuvilex,
Inc. (OTCQB:NVLX), an international biotechnology company providing
cell and gene therapy solutions for the treatment of diseases,
announced today that Mark L. Rabe, MD, ABIHM, the Scientific
Advisory Board Chairman of MMS, delivered a "Pain Medicine Grand
Rounds" presentation to pain specialists and other physicians at
the University of California, San Diego (UCSD) that dealt with the
medicinal properties of constituents of Cannabis (marijuana) that
are known as cannabinoids.
"Dr. Rabe's presentation underscores the remarkable medicinal
properties of constituents of Cannabis while demonstrating the work
underway at Medical Marijuana Sciences, including our efforts to
develop cancer treatments that combine cannabinoids with Nuvilex's
Cell-in-a-Box® technology, which we believe will result in unique
ways to combat this dreadful disease," said Kenneth L. Waggoner,
CEO and President of Nuvilex. "The physicians at UCSD have been
pioneers in research on the medicinal uses of Cannabis. This was an
important opportunity to bring Dr. Rabe's expertise to such an
influential forum."
Dr. Rabe's presentation, titled "The Science of Cannabis: Pain,
Neuroprotection, Cancer," highlighted aspects of the medicinal use
of cannabis that make it particularly useful in the treatment of
pain. Dr. Rabe offered research showing that cannabinoid molecules
act to relieve pain through at least three unique
mechanisms. Further, Dr. Rabe presented research and a U.S.
Department of Health and Human Services patent documenting the
broad antioxidant and neuroprotective properties of
cannabinoids. He also presented research showing that
cannabinoid molecules, such as THC (tetrahydrocannabinol) and CBD
(cannabidiol), have been shown to slow the growth of tumor cells,
slow the spread or metastasis of tumors and have a
tumor-preventative effect.
Dr. Rabe provides integrative holistic medical services to
patients at his San Diego medical practice, Centric Wellness, and
throughout his talk provided case studies and examples of patients
who have benefited from the use of Cannabis as medicine.
The event was sponsored by the UCSD Department of Anesthesiology
and The San Diego Society of Anesthesiologists and occurred on
April 23, 2014, with approximately 30 pain specialty and primary
care physicians from the University in attendance. UCSD has
been on the forefront of medical cannabis research since the
establishment of the Center for Medicinal Cannabis Research in
2000. UCSD physicians embrace an overall integrative approach
to medical care.
Medical Marijuana Sciences is currently in pre-clinical studies
to harness the anti-cancer properties of cannabinoids using
Nuvilex's Cell-in-a-Box® live-cell encapsulation technology as a
platform. Initial targets for the use of such products are
projected to be pancreatic and brain cancers - both very serious
and deadly forms of the disease.
About Medical Marijuana Sciences:
Medical Marijuana Sciences, Inc., a wholly owned subsidiary of
Nuvilex, Inc., is dedicated to the development of cancer treatments
based upon chemical constituents of marijuana known as
cannabinoids. To do so, it will examine ways to exploit the
benefits of Cell-in-a-Box® technology in optimizing the anticancer
effectiveness of cannabinoids against cancers while minimizing or
outright eliminating the debilitating side effects usually
associated with cancer treatments. This provides Medical
Marijuana Sciences a unique opportunity to develop "green"
approaches to fighting deadly cancers, such as those of the
pancreas, brain, breast and prostate, that affect hundreds of
thousands of individuals worldwide every year.
About Nuvilex:
Nuvilex, Inc. is a clinical stage biotechnology company focused
on developing and preparing to commercialize treatments for cancer
and diabetes based upon a proprietary cellulose-based live-cell
encapsulation technology, known as Cell-in-a-Box®. This unique
and patented technology will be used as a platform upon which
treatments for several types of cancer, including advanced,
inoperable pancreatic cancer, and diabetes are being
built. Nuvilex's treatment for pancreatic cancer involves the
widely used anticancer prodrug ifosfamide, together with
encapsulated live cells, which convert ifosfamide into its active
or "cancer-killing" form. Nuvilex is also involved in clinical
trials related to other aspects of pancreatic and other forms of
cancer.
Safe Harbor:
This press release may contain forward-looking statements
regarding Nuvilex and its future events and results that involve
inherent risks and uncertainties. The words "anticipate,"
"believe," "estimate," "expect," "intend," "plan" and similar
expressions, as they relate to Nuvilex or its management, are
intended to identify forward-looking statements. Important factors,
many of which are beyond the control of Nuvilex, that could cause
actual results to differ materially from those set forth in the
forward-looking statements include Nuvilex's ability to continue as
a going concern, delays in clinical trials or flaws or defects
regarding its products, changes in relevant legislation or
regulatory requirements, uncertainty of protection of Nuvilex's
intellectual property and Nuvilex's continued ability to raise
capital. Nuvilex does not assume any obligation to update any of
these forward-looking statements.
More information about Medical Marijuana Sciences and Nuvilex
can be found at www.medicalmarijuanasciences.com and
www.nuvilex.com. It can also be obtained by contacting
Investor Relations and Media Contacts.
CONTACT: Investor Relations Contacts:
Marlin Molinaro
Marmel Communications, LLC
Ph: 702.434.8692
mmolinarofc@aol.com
Dillon Heins
CorProminence, LLC
Ph: 218.839.9051
dillonh@corprominence.com
Media Contact:
Jules Abraham
JQA Partners, LLC
Ph: 917.885.7378
jabraham@jqapartners.com